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Angiogenesis is essential for malignant tumor growth. This has been documented for solid tumors, and there is emerging
evidence suggesting that tumor progression of hemato-lymphoid malignancies also depends on the induction of new blood vessel
formation. The most important pro-angiogenic agent is vascular endothelial growth factor (VEGF), activating VEGF receptors 1
and 2. The available data on angiogenesis in hemato-lymphoid malignancies such as acute leukemias, myelodysplastic syndromes,
myeloproliferative neoplasms, multiple myeloma and lymphomas, point towards the signiﬁcance of autocrine and paracrine
VEGF-mediated eﬀects for proliferation and survival of leukemia/lymphoma cells in addition to tumor vascularization. Anti-
angiogenic strategies have become an important therapeutic modality for solid tumors. Several anti-angiogenic agents targeting
VEGF-related pathways have are also being utilized in clinical trials for the treatment of hemato-lymphoid malignancies, and in
someinstancesthesepathwayshaveemergedaspromisingtherapeutictargets.Thisreviewsummarizesrecentadvancesinthebasic
understanding of the role of angiogenesis in hemato-lymphoid malignancies and the translation of such basic ﬁndings into clinical
studies.
1.Introduction
Newbloodvesselformation(angiogenesis)isfundamentalto
tumor growth and spread. In adults, physiological angiogen-
esis is limited to a small number of speciﬁc processes, such
as wound healing, tissue repair, and the female reproductive
cycle [1]. The pioneering work of Judah Folkman led to
the recognition that angiogenesis plays an important role in
tumordevelopment,progression,andmetastasis[2].Tumors
require nutrients and oxygen to grow, and new blood vessels,
formed by angiogenesis, provide these substrates. Tumor
blood vessels are generated by various mechanisms, such
as cooption of the existing vascular network, expansion
of the host vascular network by budding of endothelial
sprouts (sprouting angiogenesis), remodeling and expansion
of vessels by the insertion of interstitial tissue columns
into the lumen of preexisting vessels (intussusceptive angio-
genesis), and homing of endothelial cell precursors (EPC;
CEP) from the bone marrow or peripheral blood into the
endothelial lining of neovessels (vasculogenesis) [3]. Bone
marrow-derived progenitor cells contribute signiﬁcantly to
neovascularization in a variety of tumors [4, 5].
Thekeymediatorofangiogenesisisthevascularendothe-
lial growth factor (VEGF). Its expression is regulated by a
plethora of intrinsic and extrinsic factors, with hypoxia and
hypoglycemia being the major stimuli [6]. Hypoxia-induced
transcription of VEGF mRNA is mediated by binding of
hypoxia-inducible factor 1 (HIF-1) [7]. Cytokines may also
modulate angiogenesis by regulating VEGF expression, for
example, tumor necrosis factor (TNF)-α increases VEGF
mRNA in glioma cells [8], and transforming growth factor
(TGF)-βresultsintheinductionofVEGF mRNAandprotein
in human lung adenocarcinoma cells [9]. In solid tumors,
intratumoral hypoxia and HIF-1 mediation have been found
to be a key angiogenesis triggering event [10]. Less is known
about the exact trigger mechanisms of VEGF expression2 Journal of Oncology
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Figure 1: Possible vascular endothelial growth factor- (VEGF) and VEGF receptor-related (e.g., Flk-1, i.e., VEGFR-2) autocrine and
paracrine loops in hemato-lymphoid neoplasms; insert: receptor tyrosine kinase activity and signaling cascades through VEGFR-2.
in hemato-lymphoid tumors, but mechanisms analogous to
thoseobservedinsolidtumorsareanticipated[11,12].Tight
controlofangiogenesisismaintainedbyabalanceofendoge-
nous antiangiogenic and proangiogenic factors. VEGF has
a key, rate-limiting role in promoting tumor angiogenesis
and exerts its eﬀects by binding to one of three tyrosine
kinase receptors (Figure 1): VEGF receptor-1 (VEGFR-1;
fms-like tyrosine kinase-1, Flt-1), VEGFR-2 (human kinase
domain region, KDR/murine fetal liver kinase-1, Flk-1),
and VEGFR-3 (Flt-4). VEGFR-1 (ligands include VEGF-
A, -B, and placental growth factor [PIGF]) and VEGFR-2
(ligands include VEGF-A, -C, and -D) are predominantly
expressed on vascular endothelial cells, and activation of
VEGFR-2 appears to be both necessary and suﬃcient
to mediate VEGF-dependent angiogenesis and induction
of vascular permeability [13, 14]. Both receptor tyrosine
kinases are expressed in all adult endothelial cells except the
brain. VEGFR-1 is also expressed on hematopoietic stem
cells (HSC), vascular smooth muscle cells, monocytes, and
leukemic cells [15, 16], while VEGFR-2 is expressed on
endothelial progenitor cells and megakaryocytes [17, 18].
Although the exact contribution of VEGFR-1 signaling to
angiogenesis is unclear, it has been shown that VEGFR-1
directly cooperates with VEGFR-2 via heterodimerization, as
well as binding two additional VEGF homologues, VEGF-
Ba n dP I G F[ 19]. VEGFR-3, largely restricted to lymphatic
endothelial cells, binds the VEGF homologues VEGF-C and
VEGF-D and may play an important role in the regulation of
lymphangiogenesis.
VEGF and VEGFR represent signiﬁcant anticancer ther-
apy targets that elegantly bypass potential tumor-related
treatment barriers [13]. VEGF signaling inhibition has been
shown to result in signiﬁcant tumor growth delay in a wide
range of animal models [20]. In the case of VEGF, even
a single VEGF allele knock-out led to embryonic lethality
in mice [21]. The clinical beneﬁt of this approach has also
been conﬁrmed, and concerted eﬀorts in recent years have
resultedinanumberofnovelantiangiogenicagents[22].The
ﬁrst antiangiogenic agent to be approved was bevacizumab
(Avastin, Genentech), a humanized anti-VEGF monoclonal
antibody. Administration of bevacizumab, in combination
with cytotoxic chemotherapy, conferred beneﬁts to patients
with metastatic colorectal cancer, nonsquamous, nonsmall
cell lung cancer, and metastatic breast cancer [23–25], and
it is now under investigation for patients with relapsed
and refractory acute leukemia in combination with stan-
dard chemotherapy [26]. Additionally, two small-molecule
inhibitors targeting VEGFR and other kinases, sorafenib
(Nexavar, Bayer and Onyx pharmaceuticals) and sunitinib
(Sutent, Pﬁzer), have been approved based on their eﬃ-
cacy in treating renal cell- and hepatocellular carcinoma
[27, 28]. A growing number of antiangiogenics are now
either in various stages of clinical development or in
clinical use as components of standard regimens (Table 1).
The major classes of antiangiogenic therapy include (1)
direct anti-VEGF acting molecules (anti-VEGF antibod-
ies, VEGF-antisense nucleotides), (2) immunomodulatory
drugs (IMIDs) with antiangiogenic properties, (3) receptor
tyrosine kinase inhibitors that target VEGFR signaling as
well as receptors of other (proangiogenic) factors, (4) the
antiendothelial approach of metronomic therapy, and (5)
other new compounds targeting signaling downstream to
proangiogenic growth factors, such as mammalian target
of rapamycin (mTOR) inhibitors, histone deacetylases’
(HDAC) inhibitors, and proteasome inhibitors.
Several studies suggested that angiogenesis plays an
important role, as might autocrine and paracrine VEGF/
VEGFR-related loops in hemato-lymphoid malignanciesJournal of Oncology 3
Table 1: Summary of clinical trials and approved antiangiogenic therapies in hemato-lymphoid malignancies.
Drug class Target Study entities Approved for
Anti-VEGF strategies
Bevacizumab (Avastin) VEGF-A AML, MDS, CLL, CML, NHL,
MM
Metastatic colorectal cancer,
NSCLC, breast cancer
RTK inhibitors
Vatalanib VEGFR1-3, PDGFRβ, CD117 AML, PMF, MDS, CML, DLBCL,
MM
Cediranib (Recentin) VEGFR1-3, PDGFRβ, CD117 AML, MDS, CLL
Immunomodulators
Thalidomide AML, MDS, MPN, CLL, NHL,
MM MM
Lenalidomide (Revlimid) AML, MDS, CLL, NHL MM, 5q-MDS
such as acute and chronic leukemias, myelodysplastic
syndromes (MDS), myeloproliferative neoplasms (MPN),
lymphomas, and multiple myeloma (MM) [29–39]( F i g -
ure 1). Moreover, angiogenesis appears to be targeted
even by conventional chemotherapy in hemato-lymphoid
malignancies; for example, patients with acute myelogenous
leukemia (AML) show increased microvessel density (MVD)
in the bone marrow with subsequent MVD reduction under
c h e m o t h e r a p ya n dr e t u r nt on o r m a ll e v e l si nc a s e so f
complete remission (CR) [31]. This review will focus on the
current knowledge of angiogenesis and antiangiogenic ther-
apies (related to classes 1 to 3 of antiangiogenic treatment
approaches) in hemato-lymphoid malignancies.
2. Acute Leukemias
Leukemias have been ever since associated with angiogenesis
since the AML cell line HL-60 was ﬁrst used to clone the
VEGF gene [40]. The ﬁrst demonstration that leukemia
progression might be accompanied by an increase of bone
marrow vascularization was provided by Judah Folkman’s
group [41], who demonstrated that the bone marrow of
acute lymphoblastic leukemia (ALL) patients had increased
blood vessel content compared to normal counterparts.
Detailed analysis of bone marrow sections from ALL patients
ledtothedevelopmentofamodeltoillustratetheirirregular,
albeit abundant, bone marrow vasculature. Moreover, it
was also shown that urine and peripheral blood samples
fromALLpatientscontainedelevatedlevelsofproangiogenic
growthfactors,namely,basicﬁbroblastgrowthfactor(bFGF)
and VEGF, which correlated with the increase of bone
marrow angiogenesis [41, 42]. These studies raised the
question of whether the growth of other types of hemato-
lymphoid malignancies is also accompanied by increased
angiogenesis, while proving that the basic molecular/cellular
mechanisms occurring during leukemia expansion might
be similar to those seen in solid tumors. The existence of
an “angiogenesis switch”, ﬁrst proposed for solid tumors
[43], was therefore suggested to apply to hemato-lymphoid
malignancies as well. “Angiogenesis switch” in leukemia
is documented by increased bone marrow MVD (Figures
2(a) and 2(b)), increased expression of HIF-1, multiple
proangiogenicfactors(VEGF,bFGF,angiopoietin-2),soluble
VEGFR, and decreased expression of endogenous angiogen-
esis inhibitors, such as thrombospondin-1 [11, 12].
In a recent study by Nor´ en-Nystr¨ om et al. [44], MVD,
analyzed on 185 bone marrow biopsies, was higher in T-
ALL compared to B-ALL. In the B-ALL group, cases with
t(12;21) were characterized by a low MVD, while patients
with hyperdiploid leukemia showed a high MVD. There
was a correlation between MVD and white blood cell count
in high-risk B-ALL patients. In addition, patients with a
high marrow reticulin ﬁber density and high MVD had
an unfavorable outcome. Similarly, in previously untreated
AML, increased levels of plasma VEGF correlated with
reduced survival and lower remission rates [45]. Moreover,
the level of plasma/serum VEGF correlated with the number
of circulating blasts [46], indicating the probable cellular
origin of this proangiogenic factor. Such in vivo clinical
studies are further supported by in vitro demonstrations
of the capacity of leukemia cells to produce proangiogenic
growth factors such as VEGF and bFGF [47–49]. Impor-
tantly, leukemia cells release increased amounts of proan-
giogenic factors in response to proinﬂammatory molecules,
suggesting interactions with other cell types (e.g., the bone
marrow stroma). In contrast to the abundant literature
demonstrating that acute leukemia cells secrete signiﬁcant
amountsofangiogenesisactivatorssuchasVEGF,fewerstud-
ies have addressed the possibility that reduced production
of angiogenesis inhibitors by these cells might also trigger
the neovascularization process by shifting the local (bone
marrow) angiogenesis balance [50, 51]. In addition to the
modulation of bone marrow angiogenesis by leukemia cells,
itwasdemonstratedthatsubsetsofcasesexpressendothelial-
speciﬁc tyrosine kinase receptors, such as VEGFR-1, -2,
and -3, or members of the FGF receptor family [49, 52,
53]. Recent studies showed that even hematopoietic stem
cells (HSC) express VEGFR and are capable of generating
functional autocrine loops that support their proliferation
and survival [54], raising the question of whether this might
be of relevance for leukemic stem cells.4 Journal of Oncology
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Figure 2: (a) Microvascular architecture in normal bone mar-
row highlighted by CD34; note single capillaries. (b) Increased
microvessel density in acute myelogenous leukemia and in (c)
myeloproliferative neoplasm; note dilated sinus and atypical
megakaryocytes in the latter.
2.1. Antiangiogenic Therapy in Acute Leukemias. Beva-
cizumab is a humanized murine antihuman VEGF mon-
oclonal IgG1 antibody that blocks the binding of human
VEGF to its receptors, thereby also disrupting autocrine and
paracrine survival mechanisms mediated by VEGFR-1 and
VEGFR-2 [55]. In a Phase II clinical trial by Karp et al., beva-
cizumabwasadministered afterchemotherapytoadults with
refractory or relapsed AML [26]. Bevacizumab 10mg/kg
was administered on day 8 after cytarabine beginning day
1 and mitoxantrone beginning day 4. Forty-eight adults
received induction therapy and the overall response was 23
of 48 (48%), with CR in 16 (33%). Eighteen patients (14
CR and 4 partial responses) underwent one consolidation
cycle and 5 (3 CR and 2 partial responses) underwent allo-
geneic transplant. Median overall and disease-free survivals
for CR patients were 16.2 months (64%, 1 year) and 7
months (35%, 1 year), respectively. Bone marrow samples
demonstrated marked MVD decrease after bevacizumab
administration. VEGF was detected in pretreatment serum
in 67% of patients tested, increased by day 8 to 52%, and
decreased to 93% (67% undetectable) 2 hours after beva-
cizumab administration. Currently, bevacizumab is being
evaluated as treatment option for newly diagnosed AML
in combination with cytarabine and idarubicin in a phase
II study.
Thalidomide, originally marketed as a sedative and
antiemetic drug, was withdrawn from use subsequent to
reports of teratogenicity in the 1960s. The initial use
of thalidomide was the treatment of erythema nodosum
leprosum. It has been shown that thalidomide has important
immunomodulatory eﬀects in that it decreases TNF-α
synthesis and selectively modulates T-cell subsets, shifting
the T-cell population towards T helpers [56]. The interest
in thalidomide as an antineoplastic agent rose after demon-
stration of its antiangiogenic activity in a rabbit model of
corneal neovascularization that was induced in response to
bFGF [57]. This report led to thalidomide application in
MM, where it demonstrated a clinical beneﬁt. Thalidomide
and the newer IMIDs (e.g., lenalidomide) have been shown
to signiﬁcantly decrease the expression of the proangiogenic
factors VEGF and interleukin-6 (IL-6) in MM [58]. The
newer IMIDs were found to have 2-3 times more potent
antiangiogenic activity than thalidomide in various in vivo
assays [59]. The antiangiogenic activity of IMIDs has been
shown to be independent of their immunomodulatory
eﬀects [60]. In AML patients, thalidomide therapy was
assessed alone and in combination with other compounds.
In a phase II study by Thomas et al. [61], thalidomide
was analyzed in patients with relapsed or refractory AML
previously treated with cytarabine-containing regimens. A
total of 16 patients were treated with 200–800mg/d oral
thalidomide. Overall, one patient (6%) achieved CR lasting
for 36 months, and two patients had a transient reduction
in marrow blasts from 8% and 7% to less than 5%. There
wasnocorrelationbetweenreductionofangiogenesismarker
levels and response. In a phase I/II trial by Steins et al. [62],
a dose-escalating trial was performed to study the safety and
eﬃcacyofthalidomidein20AMLpatients.Thirteenpatients
were assessable for both toxicity and response, tolerating
a maximum dose of 200–400mg/d for at least 1 month.
Overall, adverse events were fatigue, constipation, rash, and
neuropathy (grades 1 to 2 in most patients). In 4 patients,
a partial response, deﬁned as reduction of at least 50% of
the blast cell inﬁltration in the bone marrow accompanied
by increases of platelet counts and hemoglobin values,
was observed. In parallel, MVD signiﬁcantly decreased in
these 5 patients during treatment with thalidomide. In a
study by Barr et al. [63], thalidomide was examined in
combination with ﬂudarabine, carboplatin, and topotecan
in 42 patients with poor prognosis AML, and 10 of 42
(24%) patients achieved a CR. Serious thrombotic adverse
events were observed in 5 patients, suggesting that the
combination of cytotoxic chemotherapy and thalidomide
may be thrombogenic despite signiﬁcant thrombocytopenia.Journal of Oncology 5
VEGF levels did not correlate with response to therapy, while
a trend towards decreased MVD was noted in patients who
achieved CR.
Small tyrosine kinase inhibitors that target VEGFR are
a further important class of antiangiogenic drugs with
application to AML, although their eﬃcacy in hemato-
lymphoid neoplasias, especially AML, might be attributable
to inhibition of a variety of pathways, particularly those
related to c-kit and ﬂt3.
Vatalanib (formerly PTK787/ZK 222584) is an oral
angiogenesis inhibitor that is active against VEGFR and
PDGFR tyrosine kinases, thereby oﬀering a novel approach
to inhibiting tumor growth [64] by interfering with the ATP
binding sites of VEGFR. In our phase I study, vatalanib was
well tolerated and showed clinical activity in a variety of
solid tumors [65]. In MM, its action primarily reduces the
number of tumor microvessels and dilates the remaining
vessels [66, 67]. Ongoing studies are now evaluating the
eﬃcacy of vatalanib in combination with imatinib in a phase
I/II trial for patients with AML, PMF, and blast phase of
chronic myelogenous leukemia. Vatalanib was studied in a
phase I clinical trial alone or in combination with cytosine-
arabinoside and daunorubicin in patients with MDS and
AML [68]. Sixty-three patients received vatalanib at doses
of 500–1000mg/bid orally. At 1000mg/bid, dose-limiting
toxicities resulting in lethargy, hypertension, nausea, emesis,
and anorexia were observed. CR was observed in 5 of 17
evaluable AML patients treated with vatalanib combined
with chemotherapy. The authors concluded that vatalanib
is generally well tolerated and can be given in combination
with chemotherapy in patients with MDS and AML. In a
recentstudybyBarbarrojaetal.[69],vatalanibwasexamined
in combination with idarubicin in 4 AML cell lines and 7
AML patient samples. Vatalanib decreased VEGF levels and
VEGFR phosphorylation in AML cells, which showed FLT3
internal tandem reduplications/mutations (ITD), raising
questions about the actual targeted tyrosine kinase (VEGFR
of ﬂt3).
Cediranib (AZD2171, Recentin) is a potent inhibitor of
both VEGFR-1 and VEGFR-2; it also has activity against c-
kit, PDGFR-β, and VEGFR-3 at nanomolar concentrations
[70]. In our study, cediranib was well tolerated up to
45mg/d in patients with a broad range of solid tumors [71],
with the most common adverse side-eﬀects being diarrhea,
dysphonia, and hypertension. In a phase I study with
cediranib in 35 AML patients, the most common adverse
events were diarrhea, hypertension, and fatigue. Six patients
experienced an objective response (3 each at 20 and 30mg).
Dose- and time-dependent reductions of soluble VEGFR-2
wereobserved,andtherewasacorrelationbetweencediranib
exposure and plasma VEGF levels [72].
3.MyelodysplasticSyndromes
InMDS,VEGFisoverexpressedbyimmaturemyeloidcellsin
thebonemarrowandassociatedwithincreasedbonemarrow
vascularity [52]. MVD parallels disease progression from
refractory anemia to secondary AML [32]. MDS patients
also have increased proangiogenic factors in peripheral
blood [73]. Higher levels of VEGF were found by immuno-
histochemistry and corroborated by reverse transcriptase-
polymerase chainreactionin patients with refractoryanemia
with excess blasts (RAEB) and RAEB in transformation
(RAEB-T), compared to patients with refractory anemia
(RA) and with ringed sideroblasts (RARS) or normal bone
marrow controls [74]. These diﬀerences were thought to
result from expression of VEGF in immature myeloid cells
in RAEB and RAEB-T. To evaluate the interplay between
angiogenesis and cytokines, we conducted a study of 89
MDS cases and showed [34] that TNF-α expression and
bone marrow MVD correlated with each other as well.
Importantly, thalidomide, a drug that modulates T-cell
function and inhibits TNF-α activity as well as angiogenesis,
is under investigation in clinical trials for the treatment of
MDS [29, 75].
3.1. Antiangiogenic Therapy in Myelodysplastic Syndromes. A
combination therapy of thalidomide and 5-azacytidine, a
hypomethylating drug, was assessed in 40 patients with MDS
and AML [76]. Hematological improvement was observed
in 15 of 36 patients (42%), stable disease was observed in 5
of 36 patients (14%), 10 of 36 patients (28%) had disease
progression, and six had CR. Lenalidomide, a synthetic
compound derived by modifying the chemical structure
of thalidomide, has also shown immunomodulatory and
antiangiogenic properties and lower adverse eﬀects rates
[77]. Lenalidomide was investigated in a study of 148 MDS
patients with 5q deletion [78]; 112 patients (76%) had a
reduced need for transfusions, and 99 (67%) eliminated the
need entirely regardless of karyotype complexity. Among
85 evaluable patients, 62 showed cytogenetic improvement,
and 38 of that 62 showed complete cytogenetic remission.
Therefore, lenalidomide was approved as a monotherapy
for the treatment of transfusion-dependent MDS patients
with 5q deletion with or without additional cytogenetic
abnormalities.
4. Multiple Myeloma
MM is characterized by proliferation of malignant plasma
cells that accumulate in the bone marrow and often produce
a monoclonal immunoglobulin. MM was the ﬁrst hemato-
lymphoid malignancy in which increased angiogenesis was
detected [36, 79]. New vessel formation in the bone marrow
seems to play an important role in the pathogenesis of
MM [80, 81]. Increased bone marrow MVD in patients
with MM also appears to be an important prognostic
factor [82]. Malignant plasma cells can secrete various
cytokines, including VEGF, bFGF, and hepatocyte growth
factor(HGF),allknownfortheirproangiogenicactivity[83].
It has been shown that MM cells are capable of secreting
VEGF in response to IL-6 stimulation, and in response to
this VEGF stimulation, microvascular endothelial cells and
bone marrow stromal cells in turn secrete IL-6, a potent
growth factor for malignant plasma cells, thus closing a
paracrine loop [84, 85]. Rajkumar et al. showed a gradual
increase of bone marrow angiogenesis along the disease6 Journal of Oncology
spectrum from monoclonal gammopathy of undetermined
signiﬁcance (MGUS) to smoldering MM, newly diagnosed
MM, and relapsed MM [86], though the expression levels
of VEGF, bFGF, and their receptors were similar among
MGUS, smoldering MM, and newly diagnosed MM [87],
suggestingthatMVDincreaseinplasmacellneoplasiascould
b eaf u n c t i o no fc h r o n o l o g y .I nar e c e n ts t u d y ,P o u re ta l .
examined 96 MM patients at diagnosis and after high-dose
chemotherapy with regard to angiogenesis factor/inhibitor
concentrations in the peripheral blood and bone marrow
plasma [88]. Based on a signiﬁcant decrease of VEGF and
hepatocyte growth factor levels, and a signiﬁcant increase
in TSP-1 thrombospondin-1 concentrations in the bone
marrow plasma of patients who achieved complete or very
good partial response versus those who had partial or no
response, they concluded that a reduction in the rate of
angiogenesis had occurred.
4.1. Antiangiogenic Therapy in Multiple Myeloma. Thalido-
mide monotherapy in a phase II trial of 84 patients with
relapsed and refractory MM who had received doses ranging
from 200 to 800mg/d resulted in an overall response rate
of 32%. The 2-year event-free and overall survival were
20 and 48%, respectively [89, 90]. In combination with
dexamethasone, the response rate was 63% compared to
41% with dexamethasone alone in patients with newly diag-
n o s e dM M[ 91]. Subsequent to these studies, thalidomide
was approved for the treatment of newly diagnosed MM.
In 2 phase III trials, lenalidomide in combination with
dexamethasone resulted in remarkable response rates and
signiﬁcantly less toxicity than thalidomide [92, 93], and
increased the response rate from 22.5% to 59.2% compared
to dexamethasone alone in patients with previously-treated
relapsed/refractory MM. Lenalidomide was approved in
combination with dexamethasone for second-line treatment
of MM.
5. MyeloproliferativeNeoplasms
The available data on angiogenesis and expression of VEGF
and VEGFR in the bone marrow of patients with BCR-
ABL1-negative MPN suggest a signiﬁcant increase of MVD
(Figure 2(c)), especially in primary myeloﬁbrosis (PMF),
which might inversely correlate with survival [30, 33, 94–
97]. The identiﬁcation of an acquired somatic mutation
in the JAK2 gene, resulting in a valine to phenylalanine
substitution at position 617 (JAK2-V617F), has provided
new insights into the pathogenesis of BCR-ABL1-negative
MPN, which is found in most patients with polycythemia
vera (PV) and in about 50% of patients with essential
thrombocythemia (ET) and PMF [98, 99]. The correlations
between angiogenesis and JAK2 status in MPN have been
addressed in two studies with contradictory results [100,
101]. In a recent study [30], we found a signiﬁcantly
increased MVD and VEGF expression in MPN compared to
controls, particularly in cases with high JAK2-V617F mutant
allele burdens. Our results imply that higher activity of Jak2-
related pathways, as observed in cases with higher JAK2-
V617F mutant allele burdens, may inﬂuence angiogenesis
in MPN. This assumption is further supported by our
observation that the number of VEGF expressing cells did
not rise concurrent with the increasing JAK2-V617F mutant
allele burden regardless of rising MVD. Further support is
provided by the study of Zhu et al. showing that H-2g,
a glucose analog of the blood group H antigen, mediates
endothelial cell chemotaxis and induces expression of the
proangiogenic factors VEGF and bFGF through pathways
involving Jak2 and phosphoinositide-3 kinase that could be
abolished by treatment with the respective inhibitors AG490
and LY294002 [102]. The importance of VEGF/Jak2/STAT5
pathways in angiogenesis is substantiated by evidence from
another study as well suggesting tight interactions between
VEGF and Jak2 [103]. Thus, it could be speculated that in
at least some hemato-lymphoid neoplasms, such as BCR-
ABL1-negativeMPN,keytumor-relatedgate-keepinggenetic
mechanisms might also directly inﬂuence angiogenesis. A
very recent study identiﬁed the JAK2-V617F mutation in
microdissectedendothelial cellsformtheliverveinsofBudd-
Chiari syndrome patients [104], raising the hypothesis that
endothelial cells in PV are direct players in the neoplastic
process.
5.1. Antiangiogenic Therapy in Myeloproliferative Neoplasms.
In a phase II study of 44 PMF patients, the eﬃcacy of
thalidomide monotherapy was assessed [105]. Seventeen
of 41 evaluable patients (41%) receiving treatment for
at least 15 days showed a response. CR (without rever-
sal of bone marrow ﬁbrosis) was achieved in 4 patients
(10%), partial response in 4 patients (10%), and hema-
tological improvements of anemia, thrombopenia, and/or
splenomegaly were observed in 9 patients (21%). A further
phase II thalidomide and placebo study assessed the eﬃcacy
of thalidomide in the treatment of anemia in PMF [106].
T h ep r i m a r yo u t c o m ew a sa2 g / li n c r e a s eo fh e m o g l o b i n
levels resulting in a 20% reduction of transfusion needs.
At 180 days, in an intention-to-treat analysis, no diﬀerence
was observed between the thalidomide and placebo groups
with regard to hemoglobin levels. In phase II studies with
lenalidomide monotherapy in patients with symptomatic
PMF, the overall response rates were 22% for anemia, 33%
for splenomegaly, and 50% for thrombocytopenia [107].
In a combination study of lenalidomide with prednisone
in 40 PMF patients [108], responses were recorded in 12
patients (30%) and are ongoing in 10 (25%), with a median
time to response of 12 weeks. Three patients (7.5%) had
partial response and nine (22.5%) had clinical improve-
ment lasting a median of 18 months. Overall response
rates were 30% for anemia and 42% for splenomegaly.
Interestingly, all eight JAK2-V617F-positive responders also
experienced a reduction of the baseline mutant allele
burden.
In another study, vatalanib was administered to 29 PMF
patients at doses of 500 or 750mg/bid. One patient (3%)
achieved CR and 5 (17%) achieved clinical improvement.
Cumulatively, these studies indicated that vatalanib had
modest activity in PMF patients [109].Journal of Oncology 7
6. Lymphomas
MVD is signiﬁcantly higher in nodal lymphomas, particu-
larly in those that are highly proliferative, than in reactive
lymph nodes (Figures 3(a) and 3(b))[ 35, 110–113]. In
extranodal lymphomas, for example, cutaneous T-cell and
B-cell lymphomas, MVD are higher than in normal skin
or benign cutaneous lymphoproliferative disorders [114–
116]. The interplay between lymphoma cells and tumor
vessels is complex [117]; lymphoma-speciﬁc chromoso-
mal aberrations such as t(8;14), t(11;14), and t(14;18)
were discovered in tumor endothelial cells, calling into
question the histogenesis of B-cell lymphoma vasculature
[118]. Lymphoma growth and progression appear to be
promoted by at least two distinct angiogenic mechanisms:
autocrine stimulation of tumor cells via expression of
VEGF and VEGFR by lymphoma cells, and paracrine
inﬂuences of the proangiogenic tumor microenvironment
on both local neovascular transformation and recruit-
ment of circulating bone marrow-derived EPC [119]. The
lymphoma microenvironment has been increasingly rec-
ognized as inﬂuencing neoplastic progression, in part by
modulating angiogenic responses to distinct proangiogenic
growth factors and cytokine milieu. In follicular lym-
phoma and diﬀuse large B-cell lymphoma (DLBCL), large-
scale gene expression proﬁling studies demonstrated that
genetic signatures expressed by stromal and inﬁltrating
immune cells deﬁned distinct prognostic groups [120,
121]. In the study of Lenz et al. [121], DLBCL gene-
expressionsignaturescorrelatedwithsurvival.Amultivariate
model,createdfromthreegene-expressionsignaturestermed
“germinal-center B-cell”, “stromal-1”, and “stromal-2”, pre-
dicted survival and was inﬂuenced by diﬀerences in immune
cells, ﬁbrosis, and particularly angiogenesis in the tumor
microenvironment.
The prognostic and predictive value (as possible treat-
ment target) of MVD and angiogenic factors in lymphomas
is still controversial due to the heterogeneity of diseases,
diﬀerent classiﬁcations, and methods for analysis (immuno-
histochemistry, serum levels of angiogenic markers, mRNA
extraction, etc.). In B-cell lymphomas, VEGF protein and
mRNA have been identiﬁed in DLBCL, mantle cell lym-
phoma (MCL), central nervous system DLBCL, and viral-
related lymphomas [122]. A large study of 200 patients
showed that high pretreatment levels of both serum VEGF
and bFGF were independent prognostic factors for survival
in multivariate analysis [123]. In a study with de novo
DLBCL treated with anthracycline-based therapy, increased
tumor vascularity was associated with poor overall survival
independent of the international prognostic index [124].
Our results on the in situ expression of VEGF in B-cell
lymphomas did not suggest a prognostic value, but showed
distinct expression patterns among the diﬀerent entities with
higher prevalence in DLBCL [35]. Since VEGF expression in
lymphomas parallels their proliferative activity [110–112],
our ﬁndings of strong VEGF expression (20 out of 109
cases, 18%) and highest MVD in DLBCL were not surprising
(Figure 2(b))[ 35]. We found no direct correlation between
increased MVD and VEGF expression in DLBCL.
(a)
(b)
Figure 3: (a) Microvascular organization of the cortical (B-cell-)
zone of a normal lymph node highlighted by CD34; note a perifol-
licular condensation of microvessels and paucity inside the follicle.
(b) Increased microvessel density in a mantle cell lymphoma case;
insert: vascular endothelial growth factor expression in a diﬀuse
large B-cell lymphoma case highlighted by immunohistochemistry.
Regarding MVD, follicular lymphoma is of special inter-
est. Several studies have recognized increased vascularization
in the perifollicular compartment of aﬀected lymph nodes
[35, 111, 113, 125]. The MVD inside the neoplastic follicles
seems similar to that in reactive lymph nodes and somewhat
lower than in DLBCL and MCL. Koster and Raemaekers
[113] showed that in follicular lymphoma, increased vas-
cularization is associated with improved clinical outcome.
Furthermore, VEGF expression seemed not to be involved in
follicular lymphoma angiogenesis.
In T-cell lymphomas, the VEGF gene is overexpressed
in both microdissected lymphoma- and endothelial cells
of angioimmunoblastic T-cell lymphoma (AITL) [126].
Accordingly,VEGFproteinexpressionwasalsofoundinboth
types of cells in lymph nodes and bone marrow samples with
AITL involvement.
In Hodgkin lymphoma (HL), VEGF is expressed along
with HIF-1, VEGFR-2, and platelet-derived endothelial
growth factor (PDGF) and its receptor (PDGFRα)a tb o t h
the protein and RNA levels [127, 128]. MVD seems also
to be increased in HL, especially in progressive disease
[128].
6.1. Antiangiogenic Therapy in Lymphomas. Given the low
proportion of DLBCL cases strongly expressing VEGF and8 Journal of Oncology
the lack of correlation between VEGF and MVD in DLBCL,
it could be anticipated that bevacizumab application in
DLBCL would be not very successful, explaining the low
observed response rates. In a phase II study of the Southwest
oncology group, single agent bevacizumab was examined
in 52 DLBCL or MCL patients in ﬁrst or second relapses
of aggressive lymphomas [129]. Patients were treated with
bevacizumab at 10mg/kg every 2 weeks, resulting in a six-
month progression-free survival of 16% with a response
rate of 2%, and median duration of response or stable
disease of 5.2 months (range 3.5–72.7). Treatment was
generally well tolerated, with grade 3 hypertension being the
most signiﬁcant adverse side eﬀect in two patients. Clinical
trials combining active chemotherapy regimens with VEGF-
targeted agents are currently in progress. Thalidomide was
evaluated in a study of 19 patients with recurrent/refractory
lymphomas until disease progression or prohibitive toxicity
was observed [130]. One patient (5%) with evidence of
recurrent gastric mucosa-associated lymphoid tissue B-cell
lymphoma achieved CR, and 3 patients (16%) achieved
stable disease. There is more promising data with lenalido-
mide treatment of indolent lymphomas, including follicular
lymphoma [131, 132], with reported response rates about
30% in pretreated patients, but the signiﬁcance of lenalido-
mide eﬀects other than modulation of angiogenesis, for
example, immunomodulation, should be considered in this
instance.
Given this strong VEGF production in AITL, it is not
surprising that the results of anti-angiogenesis therapy in
relapsed AITL are promising. There are published case
reports [133, 134] with successful bevacizumab treatment in
AITL leading to remissions lasting for several months. One
patient received 4th line bevacizumab leading to CR lasting
for 10 months; another received 5th line bevacizumab
leading to CR with such excellent tolerability that an
allogeneictransplantcouldbeplanned.Furthermore,thereis
additional small, but promising, body of evidence in favor of
thalidomide [135–137] and lenalidomide [http://www.org/
ASCOv2/Meetings/Abstracts?&vmview=abst detail view&
ID=65&abstractID=30959]. In peripheral T-cell lymphoma,
antiangiogenic substances are not yet integrated in primary,
curative-intended therapies. In the relapsed, palliative
setting, however, there are some promising data, especially
with lenalidomide (25mg/d during 3 weeks in a 4-week
cycle) [138], including unpublished data on 24 T-cell
lymphomas, including 7 patients with AITL [http://www.as-
co.org/ASCOv2/Meetings/Abstracts?&vmview=abst detail
view&confID=65&abstractID=30959]. In these heavily pre-
treated patients, the response rate was 30%, and long-lasting
remissions were also observed in the responding patients.
After a successful tumor growth delay by bevacizumab
administration in a xenograft HL model, Reiners et al.
also showed some promising eﬀects of combined gem-
citabine/bevacizumab regimen in heavily pretreated HL
patientswithmultiplerelapses[139].Inacombinationstudy,
thalidomide was examined with vinblastine in patients with
refractory HL [140]; of the 11 patients, 4 showed a partial
response to treatment (response rate 36%) and two patients
had stable disease.
7. Conclusion
Angiogenesis is essential to the development of hema-
tolymphoid malignancies, including acute and chronic
leuk emias, MPN, and lymphomas. In such instances,
VEGF/VEGFR-related pathways are the most relevant reg-
ulators of neoangiogenesis, vasculogenesis, and recruitment
of endothelial progenitor cells. Furthermore, VEGF/VEGFR
interactions can stimulate proliferation, migration, and
survival of leukemia/lymphoma cells by autocrine and
paracrine loops. Finally, in some hemato-lymphoid neo-
plasms, VEGF/VEGFR-related pathways represent a promis-
ing therapeutic target.
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